Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.

January 17, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...

Zai Lab (ZLAB) announced that China’s National Medical Products Administration, NMPA, has accepted the New Drug Application, NDA, for KarXT for ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

Please provide your email address to receive an email when new articles are posted on ... episodes and nighttime blood pressure (BP). The drug’s safety profile in this specific patient ...

A recently unsealed application for a federal wiretap offers glimpses of the serpentine path of a major drug investigation.

The Food and Drug Administration (FDA) has accepted a new drug application (NDA) with priority review for ... which was conducted in China, as well as the TRUST-II global study, both of which ...

Atara Biotherapeutics said the U.S. Food and Drug Administration placed a clinical hold on its active investigational new drug applications. The biotechnology company said the FDA put a hold on ...

"China has historically suffered greatly from the harms of drugs, which gives us a profound understanding and resolute attitude toward drug issues, particularly concerning new psychoactive ...

China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why ...